{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:52:36Z","timestamp":1787867556812,"version":"build-2784847793"},"reference-count":89,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T00:00:00Z","timestamp":1323907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0028862","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T21:58:06Z","timestamp":1323986286000},"page":"e28862","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil"],"prefix":"10.1371","volume":"6","author":[{"given":"Liyi","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia M.","family":"Huehls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Huntoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry M.","family":"Karnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies.","volume":"3","author":"DB Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1093\/nar\/19.22.6139","article-title":"Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil.","volume":"19","author":"T Samuelsson","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"8052","DOI":"10.1074\/jbc.M610621200","article-title":"5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction.","volume":"282","author":"XX Sun","year":"2007","journal-title":"J Biol Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"8939","DOI":"10.1021\/bi00085a027","article-title":"Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine.","volume":"32","author":"JR Patton","year":"1993","journal-title":"Biochemistry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1261\/rna.966208","article-title":"Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast.","volume":"14","author":"M Gustavsson","year":"2008","journal-title":"RNA"},{"key":"ref6","first-page":"632","article-title":"Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil.","volume":"54","author":"K Ghoshal","year":"1994","journal-title":"Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/nar\/gkl1084","article-title":"Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo.","volume":"35","author":"X Zhao","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1541-7786.MCR-10-0084","article-title":"The incorporation of 5-fluorouracil into RNA affects the ribonucleolytic activity of the exosome subunit Rrp6.","volume":"9","author":"RA Silverstein","year":"2011","journal-title":"Mol Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1535-7163.MCT-08-0709","article-title":"The role of floxuridine in metastatic liver disease.","volume":"8","author":"DG Power","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcb.21824","article-title":"The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine.","volume":"105","author":"A Liu","year":"2008","journal-title":"J Cell Biochem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1091\/mbc.E09-04-0303","article-title":"Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells.","volume":"20","author":"MJ Jardim","year":"2009","journal-title":"Mol Biol Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-06-0679","article-title":"Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival.","volume":"6","author":"D Wilsker","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1158\/0008-5472.CAN-03-3040","article-title":"5-fluoro-2\u2032-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells.","volume":"64","author":"LA Parsels","year":"2004","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/sj.onc.1209532","article-title":"Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil.","volume":"25","author":"HM Robinson","year":"2006","journal-title":"Oncogene"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1535-7163.MCT-06-0077","article-title":"Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.","volume":"5","author":"Z Xiao","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/sj.onc.1208309","article-title":"A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.","volume":"24","author":"Z Xiao","year":"2004","journal-title":"Oncogene"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1158\/0008-5472.CAN-11-0814","article-title":"Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells.","volume":"71","author":"AM Huehls","year":"2011","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tibs.2010.09.005","article-title":"ATR: a master conductor of cellular responses to DNA replication stress.","volume":"36","author":"RL Flynn","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.dnarep.2007.02.015","article-title":"The ATR pathway: fine-tuning the fork.","volume":"6","author":"RD Paulsen","year":"2007","journal-title":"DNA Repair (Amst)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jat.1411","article-title":"5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.","volume":"29","author":"R Matuo","year":"2009","journal-title":"J Appl Toxicol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CAD.0b013e328334b0ae","article-title":"Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?","volume":"21","author":"RA El-Awady","year":"2010","journal-title":"Anticancer Drugs"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4161\/cc.6.8.4180","article-title":"ATM activation and DNA damage response.","volume":"6","author":"MF Lavin","year":"2007","journal-title":"Cell Cycle"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00018-008-8557-5","article-title":"Participation of DNA repair in the response to 5-fluorouracil.","volume":"66","author":"MD Wyatt","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond.","volume":"10","author":"M Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e1000091","DOI":"10.1371\/journal.pbio.1000091","article-title":"Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.","volume":"7","author":"C Kunz","year":"2009","journal-title":"PLoS Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1038\/sj.onc.1206850","article-title":"MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine.","volume":"22","author":"OJ Sansom","year":"2003","journal-title":"Oncogene"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1535-7163.747.3.6","article-title":"Involvement of base excision repair in response to therapy targeted at thymidylate synthase.","volume":"3","author":"L Li","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1541-7786.MCR-08-0519","article-title":"Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.","volume":"7","author":"DR McNeill","year":"2009","journal-title":"Mol Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1158\/0008-5472.CAN-06-0540","article-title":"Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase.","volume":"66","author":"JA Fischer","year":"2006","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-06-2960","article-title":"5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.","volume":"67","author":"Q An","year":"2007","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.dnarep.2007.09.001","article-title":"Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.","volume":"7","author":"Y Luo","year":"2008","journal-title":"DNA Repair (Amst)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/carcin\/bgh347","article-title":"Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts.","volume":"26","author":"S Andersen","year":"2005","journal-title":"Carcinogenesis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/bi102046h","article-title":"Effect of the Thymidylate Synthase Inhibitors on dUTP and TTP Pool Levels and the Activities of DNA Repair Glycosylases on Uracil and 5-Fluorouracil in DNA.","volume":"50","author":"BC Grogan","year":"2011","journal-title":"Biochemistry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0959-8049(02)00610-X","article-title":"Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition.","volume":"39","author":"SJ Welsh","year":"2003","journal-title":"Eur J Cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1093\/nar\/gkr563","article-title":"UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation.","volume":"39","author":"HS Pettersen","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/em.20056","article-title":"Role of DNA mismatch repair in apoptotic responses to therapeutic agents.","volume":"44","author":"M Meyers","year":"2004","journal-title":"Environ Mol Mutagen"},{"key":"ref37","first-page":"5193","article-title":"Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.","volume":"61","author":"M Meyers","year":"2001","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1074\/jbc.M412105200","article-title":"DNA mismatch repair-dependent response to fluoropyrimidine-generated damage.","volume":"280","author":"M Meyers","year":"2005","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/CCO.0b013e32832c94bd","article-title":"Clinical implications of microsatellite instability in sporadic colon cancers.","volume":"21","author":"FA Sinicrope","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.","volume":"361","author":"PC Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval.","volume":"28","author":"PC Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.","volume":"376","author":"MW Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.","volume":"376","author":"A Tutt","year":"2010","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.1996.0163","article-title":"Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy\u2013a randomized phase II study by the Southwest Oncology Group.","volume":"61","author":"FM Muggia","year":"1996","journal-title":"Gynecol Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF00685626","article-title":"Intraperitoneal 5-fluoro-2\u2032-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.","volume":"37","author":"VK Israel","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma.","volume":"474","year":"2011","journal-title":"Nature"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","article-title":"Molecular genetics of colorectal cancer.","volume":"6","author":"ER Fearon","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer.","volume":"138","author":"CR Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF00685649","article-title":"High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer.","volume":"37","author":"JT Kamphuis","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/gyno.1995.1187","article-title":"Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.","volume":"58","author":"RJ Morgan Jr","year":"1995","journal-title":"Gynecol Oncol"},{"key":"ref51","first-page":"4308","article-title":"Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N\u2032-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.","volume":"54","author":"M Koi","year":"1994","journal-title":"Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.2536810100","article-title":"MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation.","volume":"100","author":"Y Wang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/422701","article-title":"Chromosomal instability at common fragile sites in Seckel syndrome.","volume":"75","author":"AM Casper","year":"2004","journal-title":"Am J Hum Genet"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1128\/MCB.24.19.8356-8365.2004","article-title":"A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment.","volume":"24","author":"H Luo","year":"2004","journal-title":"Mol Cell Biol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.","volume":"411","author":"SM Elbashir","year":"2001","journal-title":"Nature"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.1158\/0008-5472.CAN-10-1345","article-title":"Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.","volume":"70","author":"CJ Huntoon","year":"2010","journal-title":"Cancer Res"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.109.055178","article-title":"Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.","volume":"76","author":"JM Wagner","year":"2009","journal-title":"Mol Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/0008-5472.CAN-04-0975","article-title":"Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin.","volume":"64","author":"HR Li","year":"2004","journal-title":"Cancer Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1101\/gad.914401","article-title":"Cell cycle checkpoint signaling through the ATM and ATR kinases.","volume":"15","author":"RT Abraham","year":"2001","journal-title":"Genes Dev"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1124\/mol.105.012716","article-title":"Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.","volume":"68","author":"LM Karnitz","year":"2005","journal-title":"Mol Pharmacol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.","volume":"64","author":"I Hickson","year":"2004","journal-title":"Cancer Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bcp.2008.05.019","article-title":"Uracil in DNA: consequences for carcinogenesis and chemotherapy.","volume":"76","author":"SH Berger","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"ref63","first-page":"998","article-title":"Mechanism for exclusion of 5-fluorouracil from DNA.","volume":"40","author":"HA Ingraham","year":"1980","journal-title":"Cancer Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0026-895X(25)13666-3","article-title":"Mechanisms of excision of 5-fluorouracil by uracil DNA glycosylase in normal human cells.","volume":"43","author":"DJ Mauro","year":"1993","journal-title":"Mol Pharmacol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"39926","DOI":"10.1074\/jbc.M207107200","article-title":"hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup.","volume":"277","author":"B Kavli","year":"2002","journal-title":"J Biol Chem"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#","article-title":"Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain.","volume":"185","author":"F Petronzelli","year":"2000","journal-title":"J Cell Physiol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/tx010113b","article-title":"Characterization of the substrate specificity of a human 5-hydroxymethyluracil glycosylase activity.","volume":"15","author":"D Baker","year":"2002","journal-title":"Chem Res Toxicol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"32422","DOI":"10.1074\/jbc.M004535200","article-title":"Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase.","volume":"275","author":"F Petronzelli","year":"2000","journal-title":"J Biol Chem"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1053\/j.gastro.2007.09.003","article-title":"5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems.","volume":"133","author":"F Fischer","year":"2007","journal-title":"Gastroenterology"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1158\/0008-5472.CAN-05-4488","article-title":"The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine.","volume":"66","author":"DP Turner","year":"2006","journal-title":"Cancer Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.","volume":"13","author":"CK Donawho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1541-7786.MCR-08-0240","article-title":"Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.","volume":"6","author":"X Liu","year":"2008","journal-title":"Mol Cancer Res"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.","volume":"1","author":"AM Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1126\/science.7604266","article-title":"Mutations of GTBP in genetically unstable cells.","volume":"268","author":"N Papadopoulos","year":"1995","journal-title":"Science"},{"key":"ref75","first-page":"3721","article-title":"Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.","volume":"55","author":"MT Hawn","year":"1995","journal-title":"Cancer Res"},{"key":"ref76","first-page":"277","article-title":"Cancer Statistics, 2009.","volume":"60","author":"A Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0016-5085(99)70558-5","article-title":"Mismatch repair proficiency and in vitro response to 5-fluorouracil.","volume":"117","author":"JM Carethers","year":"1999","journal-title":"Gastroenterology"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.bjc.6605780","article-title":"5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.","volume":"103","author":"K Bracht","year":"2010","journal-title":"Br J Cancer"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4161\/cc.5.17.3184","article-title":"The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.","volume":"5","author":"MA Morgan","year":"2006","journal-title":"Cell Cycle"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2010.28.5791","article-title":"Personalizing therapy for ovarian cancer: BRCAness and beyond.","volume":"28","author":"RC Bast Jr","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gde.2008.01.016","article-title":"DNA repair deficiency as a therapeutic target in cancer.","volume":"18","author":"SA Martin","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/0008-5472.CAN-08-3610","article-title":"Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.","volume":"69","author":"JR Brody","year":"2009","journal-title":"Cancer Res"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1535-7163.MCT-10-0674","article-title":"Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.","volume":"9","author":"WH Gmeiner","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1535-7163.MCT-08-0716","article-title":"Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.","volume":"8","author":"R Humeniuk","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/1541-7786.MCR-07-2217","article-title":"The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells.","volume":"6","author":"S Kammler","year":"2008","journal-title":"Mol Cancer Res"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1358\/dot.2004.40.5.850491","article-title":"Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation.","volume":"40","author":"D Cao","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/1097-0142(19911101)68:9<1903::AID-CNCR2820680910>3.0.CO;2-9","article-title":"A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.","volume":"68","author":"GJ Peters","year":"1991","journal-title":"Cancer"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0006-2952(94)00444-Q","article-title":"Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil.","volume":"49","author":"G Pizzorno","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"ref89","first-page":"45","article-title":"Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.","volume":"3","author":"MB Yin","year":"1991","journal-title":"Cancer Commun"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0028862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T22:53:30Z","timestamp":1742079210000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0028862"}},"subtitle":[],"editor":[{"given":"Abbes","family":"Belkhiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":89,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0028862","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}